东宝生物
(300239)
| 流通市值：33.56亿 | | | 总市值：33.78亿 |
| 流通股本：5.90亿 | | | 总股本：5.94亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 520,577,739.7 | 477,954,713.78 | 532,101,881.48 | 638,830,938.38 |
| 应收票据及应收账款 | 242,173,281.19 | 278,460,634.08 | 277,427,812.53 | 247,394,630.71 |
| 其中：应收票据 | 51,395,137.63 | 65,840,948.26 | 71,225,887.8 | 66,589,742.65 |
| 应收账款 | 190,778,143.56 | 212,619,685.82 | 206,201,924.73 | 180,804,888.06 |
| 应收款项融资 | 16,525,395.15 | 66,994,488.18 | 56,386,377.46 | 40,505,616.9 |
| 预付款项 | 8,123,334.63 | 10,778,216.17 | 9,422,543.89 | 11,870,614.1 |
| 其他应收款合计 | 1,072,524.65 | 1,640,857.33 | 1,288,573.11 | 1,725,527.57 |
| 存货 | 393,658,902.3 | 372,176,041.96 | 354,463,939.1 | 380,081,920.53 |
| 其他流动资产 | 5,626,026.08 | 2,052,343.26 | 3,541,163.1 | 5,436,337.48 |
| 流动资产合计 | 1,187,757,203.7 | 1,210,057,294.76 | 1,234,632,290.67 | 1,325,845,585.67 |
| 非流动资产: | | | | |
| 长期股权投资 | 14,484,791.25 | 15,245,217.21 | 15,428,520.01 | 15,996,113.67 |
| 其他权益工具投资 | 5,621,494.45 | 5,621,494.45 | 5,621,494.45 | 5,621,494.45 |
| 投资性房地产 | 4,887,886.41 | 5,080,961.3 | 5,274,036.2 | 5,501,447.89 |
| 固定资产 | 1,018,950,316.72 | 978,505,722.58 | 998,982,296.26 | 965,685,771.63 |
| 在建工程 | 171,257,993.48 | 219,855,714.86 | 204,963,692.69 | 233,168,822.24 |
| 无形资产 | 139,317,412.36 | 141,282,179.18 | 143,264,655.1 | 140,747,390.11 |
| 开发支出 | - | - | - | 3,408,032.33 |
| 长期待摊费用 | 2,587,517.85 | 2,819,505.45 | 2,903,080.77 | 3,282,349.34 |
| 递延所得税资产 | 14,292,932.13 | 13,396,990.19 | 13,015,247.06 | 13,214,135.96 |
| 其他非流动资产 | 17,213,845.85 | 309,702.54 | 834,243 | 5,145,300.19 |
| 非流动资产合计 | 1,388,614,190.5 | 1,382,117,487.76 | 1,390,287,265.54 | 1,391,770,857.81 |
| 资产总计 | 2,576,371,394.2 | 2,592,174,782.52 | 2,624,919,556.21 | 2,717,616,443.48 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 188,217,456.65 | 168,743,307.52 | 216,065,961.4 | 237,062,511.74 |
| 其中：应付票据 | 92,040,800 | 59,428,000 | 82,574,000 | 114,974,000 |
| 应付账款 | 96,176,656.65 | 109,315,307.52 | 133,491,961.4 | 122,088,511.74 |
| 合同负债 | 8,435,789.69 | 11,969,485.06 | 9,916,836 | 13,707,412.13 |
| 应付职工薪酬 | 12,568,806.26 | 12,217,578.89 | 12,767,822.38 | 10,969,727.73 |
| 应交税费 | 5,166,283.15 | 13,651,192.29 | 10,816,975.92 | 7,931,224.34 |
| 其他应付款合计 | 11,464,699.62 | 11,128,119.03 | 11,356,603.16 | 127,019,723.52 |
| 一年内到期的非流动负债 | 9,769,618.55 | 8,270,093.58 | 7,709,177.62 | 427,033.15 |
| 其他流动负债 | 35,928,839.64 | 43,260,479.2 | 55,138,706.72 | 45,161,970.97 |
| 流动负债合计 | 271,551,493.56 | 269,240,255.57 | 323,772,083.2 | 442,279,603.58 |
| 非流动负债: | | | | |
| 长期借款 | 63,840,000 | 76,073,833.34 | 36,050,000 | 42,766,700 |
| 应付债券 | 444,893,805.97 | 440,345,407.64 | 435,848,632.74 | 431,491,800.37 |
| 长期应付款 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 |
| 递延收益 | 46,145,575.32 | 47,224,157.2 | 48,506,660.87 | 40,098,857.8 |
| 递延所得税负债 | 34,235,227.01 | 30,964,081.81 | 31,318,912.71 | 30,289,117.81 |
| 非流动负债合计 | 599,114,608.3 | 604,607,479.99 | 561,724,206.32 | 554,646,475.98 |
| 负债合计 | 870,666,101.86 | 873,847,735.56 | 885,496,289.52 | 996,926,079.56 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 593,607,933 | 593,607,933 | 593,607,062 | 593,606,491 |
| 其他权益工具 | 25,098,497.28 | 25,098,497.28 | 25,098,817.24 | 25,099,026.87 |
| 资本公积 | 644,381,265.12 | 644,381,265.12 | 644,376,203.98 | 644,372,602.66 |
| 减:库存股 | 56,114,846.36 | 40,146,532.65 | - | - |
| 盈余公积 | 65,046,867.91 | 65,046,867.91 | 65,046,867.91 | 58,727,164.16 |
| 未分配利润 | 433,805,139.17 | 430,458,491.31 | 411,413,672.26 | 398,024,350.43 |
| 归属于母公司股东权益合计 | 1,705,824,856.12 | 1,718,446,521.97 | 1,739,542,623.39 | 1,719,829,635.12 |
| 少数股东权益 | -119,563.78 | -119,475.01 | -119,356.7 | 860,728.8 |
| 股东权益合计 | 1,705,705,292.34 | 1,718,327,046.96 | 1,739,423,266.69 | 1,720,690,363.92 |
| 负债和股东权益合计 | 2,576,371,394.2 | 2,592,174,782.52 | 2,624,919,556.21 | 2,717,616,443.48 |
| 公告日期 | 2025-08-29 | 2025-04-24 | 2025-04-24 | 2024-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |